Pre-Exposure Prophylaxis

A pre-exposure prophylaxis (PrEP) therapy for COVID-19, Evusheld (AstraZeneca), is available under Emergency Use Authorization. Evusheld is a combination of two long-acting monoclonal antibodies (Tixagevimab co-packaged with Cilgavimab).

Patient Eligibility and Administration

Evusheld can only be used in patients who are 12 years of age and older weighing at least 40kg or 88 pounds. In addition, Evusheld can only be used on patients:

• Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and 
  • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reation) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

The following are limitations of authorized use:

• EVUSHELD is not authorized for use in individuals:
  • For treatment of COVID-19, or
  • For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
• ​Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
• In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

Eligibility will be determined by healthcare professionals. Evusheld is administered as two seperate conscutive intramuscular injections.

Resources

Evusheld EUA Letter of Authorization (EUA)

Evusheld Provider Fact Sheet

Evusheld Fact Sheet for Patients and Caregivers

Frequently Asked Questions on the Emergency Use Authorization for Evusheld

Questions

For questions about this treatment, please contact your healthcare provider.